Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARQT NASDAQ:IMCR NASDAQ:KOD NASDAQ:SPRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$14.99+0.2%$14.13$7.86▼$17.75$1.78B1.771.49 million shs1.25 million shsIMCRImmunocore$33.91-0.1%$34.12$23.15▼$40.52$1.70B0.77245,435 shs441,473 shsKODKodiak Sciences$7.80-5.3%$4.33$1.92▼$11.60$434.77M2.28576,965 shs618,579 shsSPRYARS Pharmaceuticals$17.75-3.3%$16.25$8.91▼$18.90$1.80B0.91.27 million shs728,716 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics+0.67%+4.32%+8.88%+1.42%+48.56%IMCRImmunocore-3.50%-8.10%+9.06%+11.39%-15.42%KODKodiak Sciences-6.79%+62.20%+122.70%+98.08%+153.54%SPRYARS Pharmaceuticals+2.69%+2.80%+0.82%+31.82%+67.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARQTArcutis Biotherapeutics2.0794 of 5 stars3.41.00.00.02.81.70.6IMCRImmunocore1.4797 of 5 stars3.30.00.00.02.42.50.0KODKodiak Sciences3.2776 of 5 stars2.02.00.04.62.23.30.0SPRYARS Pharmaceuticals3.1646 of 5 stars3.61.00.00.03.54.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARQTArcutis Biotherapeutics 2.83Moderate Buy$19.4029.42% UpsideIMCRImmunocore 2.55Moderate Buy$58.8973.66% UpsideKODKodiak Sciences 2.00Hold$9.0015.38% UpsideSPRYARS Pharmaceuticals 3.17Buy$31.0074.65% UpsideCurrent Analyst Ratings BreakdownLatest KOD, ARQT, IMCR, and SPRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/25/2025ARQTArcutis BiotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$18.006/2/2025IMCRImmunocoreHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.005/27/2025IMCRImmunocoreDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$65.005/23/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.005/8/2025IMCRImmunocoreOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$85.00 ➝ $86.00(Data available from 7/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARQTArcutis Biotherapeutics$196.54M9.09N/AN/A$1.35 per share11.10IMCRImmunocore$310.20M5.49N/AN/A$7.20 per share4.71KODKodiak SciencesN/AN/AN/AN/A$2.86 per shareN/ASPRYARS Pharmaceuticals$89.15M19.55$0.01 per share2,166.90$2.64 per share6.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARQTArcutis Biotherapeutics-$140.04M-$1.040.00N/AN/A-60.95%-80.66%-32.94%8/6/2025 (Estimated)IMCRImmunocore-$51.09M-$0.430.00N/AN/A-6.48%-5.86%-2.09%8/6/2025 (Estimated)KODKodiak Sciences-$176.21M-$3.630.00N/AN/AN/A-115.71%-54.17%8/13/2025 (Estimated)SPRYARS Pharmaceuticals$8M-$0.160.00N/AN/A-16.11%-6.94%-5.60%8/5/2025 (Estimated)Latest KOD, ARQT, IMCR, and SPRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025IMCRImmunocore-$0.21N/AN/AN/AN/AN/A8/13/2025Q2 2025KODKodiak Sciences-$1.01N/AN/AN/AN/AN/A8/6/2025Q2 2025ARQTArcutis Biotherapeutics-$0.19N/AN/AN/A$72.70 millionN/A8/5/2025Q2 2025SPRYARS Pharmaceuticals-$0.42N/AN/AN/A$12.92 millionN/A5/14/2025Q1 2025KODKodiak Sciences-$0.89-$1.09-$0.20-$1.09N/AN/A5/14/2025Q1 2025SPRYARS Pharmaceuticals-$0.35-$0.35N/A-$0.35$7.48 million$7.97 million5/7/2025Q1 2025IMCRImmunocore-$0.35$0.10+$0.45$0.10$108.82 million$125.13 million5/6/2025Q1 2025ARQTArcutis Biotherapeutics-$0.21-$0.20+$0.01-$0.20$64.80 million$65.85 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/AIMCRImmunocoreN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARQTArcutis Biotherapeutics0.753.553.37IMCRImmunocore1.036.366.31KODKodiak SciencesN/A4.624.62SPRYARS Pharmaceuticals0.3011.0010.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARQTArcutis BiotherapeuticsN/AIMCRImmunocore84.50%KODKodiak Sciences89.06%SPRYARS Pharmaceuticals68.16%Insider OwnershipCompanyInsider OwnershipARQTArcutis Biotherapeutics9.40%IMCRImmunocore10.40%KODKodiak Sciences45.90%SPRYARS Pharmaceuticals33.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARQTArcutis Biotherapeutics150119.20 million108.00 millionOptionableIMCRImmunocore32050.23 million45.01 millionOptionableKODKodiak Sciences9052.76 million28.55 millionOptionableSPRYARS Pharmaceuticals9098.21 million65.31 millionOptionableKOD, ARQT, IMCR, and SPRY HeadlinesRecent News About These CompaniesAnalysts Estimate ARS Pharmaceuticals, Inc. (SPRY) to Report a Decline in Earnings: What to Look Out forJuly 29 at 11:10 AM | zacks.comSchulhoff & Co. Inc. Purchases Shares of 40,500 ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)July 28 at 8:17 AM | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Rating Lowered to Sell at Wall Street ZenJuly 28 at 3:41 AM | americanbankingnews.comKnights of Columbus Asset Advisors LLC Invests $543,000 in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)July 27 at 5:09 AM | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Position Lowered by Royce & Associates LPJuly 27 at 4:25 AM | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Downgraded to Sell Rating by Wall Street ZenJuly 26 at 2:59 AM | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Purchased by Legato Capital Management LLCJuly 24, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Bought by FAS Wealth Partners Inc.July 19, 2025 | marketbeat.comEURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)July 18, 2025 | globenewswire.comWhat Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing'July 15, 2025 | sharewise.comSARS Pharmaceuticals, Inc. (SPRY) is a Great Momentum Stock: Should You Buy?July 15, 2025 | zacks.comWall Street Analysts See a 78.77% Upside in ARS Pharmaceuticals, Inc. (SPRY): Can the Stock Really Move This High?July 15, 2025 | zacks.comWhat Makes ARS Pharmaceuticals, Inc. (SPRY) a Good Fit for 'Trend Investing'July 15, 2025 | zacks.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Rating of "Buy" by BrokeragesJuly 11, 2025 | marketbeat.comARS Pharmaceuticals: High Risk High Reward Rollout Of No Needle EpinephrineJuly 10, 2025 | seekingalpha.comARS Pharmaceuticals: 'Betting On The Come'July 9, 2025 | seekingalpha.comARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 4.6% - Should You Buy?July 7, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Raises Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)July 6, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $254,850.00 in StockJuly 4, 2025 | insidertrades.comInsider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells 15,000 Shares of StockJuly 3, 2025 | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Major Shareholder James E. Flynn Sells 740,149 SharesJuly 2, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKOD, ARQT, IMCR, and SPRY Company DescriptionsArcutis Biotherapeutics NASDAQ:ARQT$14.99 +0.03 (+0.20%) Closing price 04:00 PM EasternExtended Trading$14.99 +0.00 (+0.01%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Immunocore NASDAQ:IMCR$33.91 -0.03 (-0.09%) Closing price 04:00 PM EasternExtended Trading$33.88 -0.02 (-0.07%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.Kodiak Sciences NASDAQ:KOD$7.80 -0.44 (-5.34%) Closing price 04:00 PM EasternExtended Trading$7.80 +0.00 (+0.06%) As of 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.ARS Pharmaceuticals NASDAQ:SPRY$17.75 -0.60 (-3.27%) Closing price 04:00 PM EasternExtended Trading$17.76 +0.02 (+0.08%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas RCL Stock Sinks After Earnings—Is a Buying Opportunity Ahead? Amazon's Pre-Earnings Setup Is Almost Too Clean—Red Flag? Should Investors Lock Arms With Buffett and Dive Into POOL Stock? Deckers Stock Recovers on Strong Earnings—More Upside Ahead? Can HCA Healthcare Revive the Market’s Weakest Sector? CrowdStrike Stock Eyes Next Move With AI in Focus Palantir Stock Gains Firepower From Pentagon AI Deals 3 Reasons Tesla's Post-Earnings Hangover Looks Like a Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
